Cannabis finance news

AusCann offloads 52% of CannPal to founder Layton Mills in move to ‘unlock potential’ of animal business

by Steve Jones March 13, 2023April 30, 2024

AusCann has divested 52% of animal health specialist CannPal in a move it believes will unlock […]

Cannabiz launches awards program to celebrate an industry changing lives

by cannabiz team March 9, 2023April 30, 2024

Hope for Medlab to continue ‘in some shape or form’ as consultants weigh up variety of potential deals

by Steve Jones March 9, 2023April 30, 2024

Company news: Vitura Health; Puro; MGC Pharma; Incannex; Cann Global

by Steve Jones March 8, 2023April 30, 2024

Bod Science clears stability hurdle for Aqua Phase deal but PK study delayed

by Steve Jones March 7, 2023April 30, 2024

Medlab goes up for sale as directors appoint external consultants

by Steve Jones March 7, 2023April 30, 2024

Medlab cancels studies and directors depart as ASX suspends shares

by Steve Jones March 2, 2023April 30, 2024

Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira

by Martin Lane and Steve Jones March 1, 2023April 30, 2024

Company news: Eqalis/Novachem; Cann Group; Vitura Health; Incannex; Lyphe Group

by Steve Jones and Martin Lane March 1, 2023April 30, 2024

Cann Group to focus on ‘production at scale’ as new CEO beds down

by Steve Jones February 28, 2023April 30, 2024